Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

In the most recent trading session, Gilead Sciences (GILD) closed at $91.09, indicating a +0.44% shift from the previous trading day.

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, with a market cap of $115.3 billion, is a global ...

Oppenheimer previewed the upcoming year for the firm’s Biotechnology coverage and said the firm’s top ideas for 2025 are Capricor (CAPR), ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for more than a decade, the performance record favored growth ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.13 which represents a decrease of $-1.26 or -1.35% from the prior close of $93.39. The stock opened at $93.5 and touched a low ...